Table 3.
Treatment Settings
| Number of chemotherapy lines in recurrent or metastatic setting |
Among the whole cohort (N = 198) |
Among patients eligible for inclusion in a clinical trial (N = 131) |
|---|---|---|
| No. of patients (%) | No. of patients (%) | |
| 1 |
74 (37) |
33 (25) |
| 2 |
47 (24) |
37 (28) |
| 3 |
44 (22) |
33 (25) |
| 4 |
23 (12) |
19 (15) |
| 5 or more |
10 (5) |
9 (7) |
|
Chemotherapy drug used |
|
|
| Taxanes |
177 (89) |
122 (93) |
| Including recurrent or metastatic setting |
162 (82) |
116 (89) |
| CDDP or Carboplatin |
185 (93) |
127 (97) |
| Including recurrent or metastatic setting |
154 (78) |
114 (87) |
| 5FU |
78 (39) |
62 (47) |
| Including recurrent or metastatic setting |
36 (18) |
32 (24) |
| Cetuximab |
144 (73) |
103 (79) |
| Including recurrent or metastatic setting |
134 (68) |
100 (76) |
| Capecitabine in recurrent or metastatic setting |
27 (14) |
23 (18) |
| Methotrexate in recurrent or metastatic setting |
67 (34) |
39 (30) |
| Novel agent tested in a clinical trial in recurrent or metastatic setting |
27 (14) |
27 (21) |
|
Drug combination used in first line of the recurrent/metastatic disease |
|
|
| Platinum based combination |
143 (72) |
103 (79) |
| Cisplatin + taxanes |
46 (23) |
40 (31) |
| Carboplatin + taxanes |
69 (35) |
40 (31) |
| Platinum without taxanes |
28 (14) |
23 (18) |
| Including CDDP 5FU and cetuximab combination |
11 (6) |
10 (8) |
| Taxanes and cetuximab combination |
14 (7) |
8 (6) |
| Monotherapy |
34 (17) |
13 (10) |
| Clinical trials testing not approved regimens | 7 (4) | 7 (5) |
CDDP = Cisplatin ; 5FU = 5-Fluorouracil.